Premium
Effects of 5‐HT 3 antagonism on postprandial gastric volume and symptoms in humans
Author(s) -
Kuo B.,
Camilleri M.,
Burton D.,
Viramontes B.,
McKinzie S.,
Thomforde G.,
O'Connor M. K.,
Brinkmann B. H.
Publication year - 2002
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2002.01144.x
Subject(s) - postprandial , medicine , bloating , nausea , gastric emptying , placebo , gastroenterology , meal , ingestion , prokinetic agent , stomach , pathology , alternative medicine , insulin
Background: Alosetron reduces symptoms of dyspepsia, but the physiological basis for the symptomatic benefit is unclear. Aim: To assess 5‐HT 3 antagonism on postprandial gastric volume and symptoms after ingestion of maximum tolerable volume of a liquid meal. Methods: In 36 healthy volunteers, we assessed effects of placebo, 0.5 and 1 mg b.d. alosetron on fasting and postprandial gastric volumes (using single photon emission computed tomography) and symptoms based on 100 mm VAS, 30 min after maximum volume ingested. Results: The 5‐HT 3 antagonist reduced postprandial symptoms (aggregate score: P < 0.05), nausea ( P < 0.001), and tended to reduce bloating ( P =0.08). Both 0.5 and 1 mg alosetron reduced nausea ( P < 0.025); 1 mg alosetron reduced aggregate symptoms ( P < 0.05) and bloating ( P < 0.05). Effects on pain ( P =0.19) and fullness ( P =0.14) were not statistically significant. There were no significant effects of the 5‐HT 3 antagonist on volume of meal tolerated or on SPECT‐measured fasting or postprandial gastric volumes. Conclusion: 5‐HT 3 antagonism reduces aggregate symptoms, nausea and bloating after a liquid meal without increase in gastric volumes, suggesting a role for 5‐HT 3 in afferent functions in healthy humans during the postprandial period.